Access cutting-edge ischemic stroke treatment through this clinical trial at a research site in Charlottesville. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Charlottesville location
Preparing your pre-screening questions…
Access ischemic stroke specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ischemic stroke treatment provided free
Check if you qualify for this ischemic stroke clinical trial in Charlottesville, VA
No-Cost Study Care
Local to Charlottesville
Convenient for VA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels. After a patient has this kind of stroke, they are often given a combination of two blood thinners to prevent it from happening again. One of these blood thinners, called clopidogrel, is less effective in some people due to differences in their DNA. Clopidogrel needs to be activated by a specific enzyme in the body known as CYP2C19. This enzyme does not work as well if there are variations in the section of DNA that tells the body how to make CYP2C19. It can be predicted who has less CYP2C19 enzyme activity with a genetic test. If these patients are given a different blood thinner, it can reduce their risk of another stroke compared to if they are given clopidogrel. The main questions this study aims to answer are: * What are the best strategies to implement this genetic test in the hospital? * Does implementation of this genetic test change providers' decisions on which medication to prescribe after a participant has a stroke? Participants in this study will have a genetic test done onsite looking for variations in the section of DNA that tells the body how to make CYP2C19. This genetic test will only look for 11 known variations; the genome will not be sequenced. The investigators will alert the doctor of the patient's test results so they can prescribe the appropriate blood thinner. Through this, the investigators will learn the best practices for successful implementation of this genetic test.
Sponsor: University of Virginia
Yes, this clinical trial (NCT06292117) has an active research site in Charlottesville, VA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for ischemic stroke treatment options in Charlottesville, VA, this clinical trial (NCT06292117) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Charlottesville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ischemic stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all ischemic stroke clinical trials near you to find additional studies recruiting in your area.
See all stroke clinical trials recruiting in Charlottesville — not just this study.
Browse Stroke Trials in Charlottesville →